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The immunosuppressive regimens currently used in transplantation to prevent allograft
destruction by the host’s immune system have deleterious side effects and fail to control
chronic rejection processes. Induction of donor-speciﬁc non-responsiveness (i.e., immuno-
logical tolerance) to transplants would solve these problems and would substantially
amelioratepatients’qualityoflife.Ithasbeenproposedthatbonemarroworhematopoietic
stem-cell transplantation, and resulting (mixed) hematopoietic chimerism, lead to immuno-
logical tolerance to organs of the same donor. However, a careful analysis of the literature,
performed here, clearly establishes that whereas hematopoietic chimerism substantially
prolongs allograft survival, it does not systematically prevent chronic rejection. Moreover,
the cytotoxic conditioning regimens used to achieve long-term persistence of chimerism
are associated with severe side effects that appear incompatible with a routine use in
the clinic. Several laboratories recently embarked on different studies to develop alterna-
tive strategies to overcome these issues. We discuss here recent advances obtained by
combining regulatory T cell infusion with bone-marrow transplantation. In experimental
settings, this attractive approach allows development of genuine immunological tolerance
to donor tissues using clinically relevant conditioning regimens.
Keywords:transplantationtolerance,hematopoieticchimerism,regulatoryTlymphocytes,passivetolerance,active
tolerance, chronic rejection
INTRODUCTION
The immunosuppressive regimens developed since the discovery
of cyclosporine A showed ever increasing efﬁciency in reducing
the severity and occurrence of acute rejection episodes. Recently,
a systematic analysis of the literature ﬁrmly identiﬁed acute rejec-
tion events as a bad prognosis factor for long-term graft survival
(Wu et al.,2009). Since immunosuppressive drugs efﬁciently con-
trol acute rejection, this explains how they signiﬁcantly improved
allograft survival over the past 40years despite failing to have a
direct impact on chronic rejection. The failure of current treat-
ments to control chronic rejection processes combined with their
deleteriousside-effectsurgentlycallfordevelopmentofnovelther-
apies against allograft rejection (Kahan,2003;Meier-Kriesche and
Kaplan, 2011).
Duringlymphocytedevelopmentinprimarylymphoidorgans,
andduetotherandomrearrangementof genesencodingtheanti-
genreceptor,manyautospeciﬁcTandBcellprecursorsarise.Since
such cells would cause devastating autoimmune pathology, the
natural mechanisms involved in the induction of self-tolerance
play a crucial role in the survival of the species (Waldmann,
2010). Self-tolerance is deﬁned as a state in which autoim-
mune attack is either prevented or deviated to non-detrimental
responses (Walker and Abbas, 2002; Hogquist et al., 2005). It
allows development of protective immunity and is therefore very
speciﬁc. It appears very attractive to manipulate the mechanisms
involved in self-tolerance in order to make them prevent allograft
rejection. If successful, this would allow for indeﬁnite survival of
grafts.
TOLERANCE-INDUCTION BY CELLS OF HEMATOPOIETIC
ORIGIN: PROOF OF PRINCIPLE
Several layers of complementary mechanisms ensure tolerance to
self-antigens. Interestingly, considerable insight into these mech-
anisms was obtained through transplantation models and by
manipulating the development of the immune system early in life,
during embryogenesis or in neonates. Owen (1945) ﬁrst observed
that dizygotic twin cattle,that almost invariably develop placental
anastomosis, “have identical blood types” as adults and he con-
cluded “the critical interchange is of embryonal cells ancestral
to the erythrocytes”. Later, Billingham, Medawar, and colleagues
showed that these chimeric twins “accepted” each other’s skins
when grafted later in life (Billingham et al.,1952). In a 1953 land-
mark paper, the same group showed that skin allograft survival
could be substantially prolonged by injecting a single-cell sus-
pension of donor tissues in utero or into neonates (Billingham
et al., 1953). Such treatment led to varying levels of hematopoi-
etic chimerism, which was later shown to be critically involved in
allograft survival (Lubaroff and Silvers, 1973;Wood and Streilein,
1982;Wren et al., 1993;Alard et al., 1995).
In the two systems described above, lymphocytes developed in
thepresenceof(andthuslearnedtobetolerantto)donorantigens.
However,inadultsthesituationismorecomplicatedas,inaddition
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todevelopinglymphocytes,preexistingdonor-speciﬁcmaturecells
would also need to be rendered tolerant. To bypass this concern,
several laboratories decided to deplete the pool of mature T cells
(Main and Prehn, 1955; Trentin, 1956; Brocades Zaalberg et al.,
1957). These groups ﬁrst experimented this approach through
the elimination of all hematopoietic cells. Recipient mice were
lethally irradiated or treated with cytotoxic drugs, reconstituted
with donor bone marrow, and grafted with skin. These strate-
gies invariably led to substantially increased survival of homo-
and xenografts. More recently,Ildstad and Sachs (1984) deﬁnitely
validated these observations by inducing long-term survival of
allogenic and xenogenic skin grafts using a comparable approach.
Similar results were obtained in the rat for heart and skin grafts
(Colson et al., 1995b; Orloff et al., 1995). Combined, these obser-
vations clearly demonstrated that hematopoietic chimerism leads
to prolonged survival of allografts.
CELLS OF HEMATOPOIETIC ORIGIN INDUCE T CELL
TOLERANCE BY INDUCTION OF APOPTOSIS AND ANERGY
To address the question of how cells of hematopoietic origin
induce tolerance, researchers needed a means to identify T cell
precursors speciﬁc for a given antigen. Kappler et al. (1987b)
showed that practically all T cells expressing the variable TCR
segment Vβ17a, representing up to 15% of the T cell repertoire
in certain mouse-strains, recognized the MHC class II mole-
cule I-E. Given that they had developed an antibody against this
Vβ domain, the mechanisms involved in T cell tolerance to I-E
could now be analyzed. It was shown in I-E expressing mice that
Vβ17a+ T cell precursors were eliminated at an immature stage
during thymic development (Kappler et al., 1987a). The follow-
ing year, the same authors further characterized this mechanism
and showed that clonal deletion requires the expression of the
negatively selecting ligand by thymic cells of hematopoietic origin
(Kappler et al., 1988). Many other illustrations of clonal deletion
of T cells expressing given TCR Vβ segments by endogenous or
exogenous superantigens have since been published (MacDonald
et al.,1988b; Luther and Acha-Orbea, 1997).
Could thymic elimination of reactive clones also be involved in
the neonatal induction of tolerance to alloantigens? This ques-
tion was addressed by MacDonald et al. (1988a) who showed
that the transfer of superantigen-expressing spleen cells into
neonatesleadtotheintrathymicdeletionof superantigen-reactive
Tcells.Similarconclusionswererapidlydrawnbyothers(Streilein,
1991).Later,intrathymicdeletionofdonor-speciﬁcprecursorswas
also reported in adult mixed hematopoietic chimeras using TCR
transgenic cells as a tracer population (Manilay et al., 1998).
Thus,thymiccellsof hematopoieticoriginareinvolvedindele-
tion of autospeciﬁc T cell-precursors and mixed hematopoietic
chimerism leads to deletion of alloreactive cells. Using thymic
organ cultures to analyze the involvement of different stromal
cells, it was shown that dendritic cells (DC) are critically involved
in this process (Matzinger and Guerder, 1989; Jenkinson et al.,
1992; Anderson et al., 1998). This was further conﬁrmed using
a transgenic mouse model in which TCR ligand-expression was
essentially restricted to DC using the CD11c promoter (Brocker
et al., 1997). Among the thymic DC subtypes, both Sirpα+
and Sirpα − conventional DC have been implicated in central
tolerance-induction by deletion (Wu and Shortman, 2005; Baba
et al., 2009). However, other populations of hematopoietic cells
mayalso playaroleinthisprocess,includingCD4+CD8+ thymo-
cytes, thymic macrophages and B cells (Pircher et al., 1992, 1993;
Kleindienst et al., 2000), and circulating peripheral DC (Bonasio
et al.,2006).
Combined, the data discussed thus far showed that DC, and
potentially other cells of hematopoietic origin, contribute to tol-
erance induction by elimination of developing thymocytes. Using
conditioningregimensthattotallydepletehostTcellsbeforebone-
marrowtransplantation,itwasproposedthatthismechanismwas
necessary and sufﬁcient for maintenance of tolerance and that
peripheral mechanisms do not contribute to this process (Khan
et al.,1996). However,other mechanisms could be involved when
less aggressive regimens are used. In normal mice,it has been pro-
posed that deletion of autospeciﬁc T cells that escaped thymic
selection could also occur in peripheral lymphoid organs and
could be involved in the maintenance of self-tolerance (Russell,
1995). To test if similar mechanisms were involved in induction
of tolerance to alloantigens following bone-marrow transplan-
tation, Wekerle et al. (1998) tracked T cells speciﬁc for a given
superantigeninthymectomizedmicetransplantedwithallogeneic
bone-marrow under cover of CTLA4-Ig and antibody to CD154
(“co-stimulatory blockade”). They observed a rapid deletion of
donor-speciﬁc host T cells from the peripheral CD4+ compart-
ment. This observation was later conﬁrmed using a TCR trans-
genic mouse model (Kurtz et al., 2004) and it was further shown
that peripheral deletion relies essentially on two types of mecha-
nisms:activation-inducedcelldeath,aFas-dependentprocessthat
can be promoted by IL-2 and that leads to apoptosis of activated
T cells when restimulated with high doses of antigen (Lenardo,
1991; Ju et al.,1995; Russell,1995); and passive cell death or death
“by neglect,” a Fas-independent process that can be prevented by
overexpressionof Bcl-2orBcl-xL andthatleadstoTcellapoptosis
when stimulated with low dose of antigen and/or in the absence
of co-stimulatory signals (Boise et al.,1995;Van Parijs et al.,1996;
Wekerle et al., 2001). It was also shown that in addition to DC,
other populations of hematopoietic cells such as B cells have the
capacitytodeleteallospeciﬁcprecursorsfromtheperipheralTcell
compartment (Fehr et al., 2008a,b). Finally, hematopoietic cells
can also cause T cell tolerance by inducing a non-responsive state
called clonal anergy (Rammensee et al., 1989; Tomita et al., 1994;
Hawiger et al., 2001). Combined, the cited reports clearly show
that cells of hematopoietic origin can induce “passive” tolerance
(i.e., apoptosis and anergy).
CAN HEMATOPOIETIC CELLS INDUCE ACTIVE REGULATORY
MECHANISMS?
T lymphocytes from chimeric mice in which radioresistant cells
express MHC molecules but hematopoietic cells do not, vigor-
ouslyreacttoself-antigensinvitro(vanMeerwijkandMacDonald,
1999) and in some well-deﬁned experimental conditions in vivo
(Hudrisier et al., 2003). Combined with the observations listed
above, this shows that hematopoietic cells play a central role in
the deletion and/or functional inactivation of self-reactive pre-
cursors. However, passive mechanisms are not sufﬁcient to fully
controlself-reactivity.IndividualscarryingamutatedFOXP3gene
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develop the rapidly lethal autoimmune syndrome immuno dys-
function,polyendocrinopathy,enteropathy,X-linked(IPEX).This
is explained by the fact that Foxp3 is required for the program-
ming of a population of regulatory CD4+ T lymphocytes (Treg)
that inhibit and/or divert innate and adaptive immune responses,
mainly those directed against self-antigens. Genuine tolerance to
self, and consequently probably to non-self-antigens, therefore
requires Treg (Fontenot and Rudensky, 2005; Sakaguchi et al.,
2006; Shevach et al.,2006).
Given their central (though not exclusive) role in the control
of autoimmune responses, it was probably not a very surprising
ﬁndingthattheTregrepertoireisstronglyenrichedinautospeciﬁc
cells (Romagnoli et al., 2002; Hsieh et al., 2004). Development
of self-antigen-speciﬁc Treg in the thymus depends on inter-
action of developing precursors with MHC/self-peptide ligands
expressedbythymicepithelialcells(Bensingeretal.,2001;Romag-
noli et al., 2005; Ribot et al., 2006, 2007; Aschenbrenner et al.,
2007). Moreover, the transplantation of allogeneic thymic anla-
gen (i.e., the initial cluster of pluripotent embryonic cells from
which the thymus will develop) into mice induces Treg-mediated
tolerance to subsequent skin grafts of the same donor, again
showing that thymic epithelial cells can select antigen-speciﬁc
Treg (Le Douarin et al., 1996). However, the capacity to trigger
Treg differentiation in the thymus is not a property restricted to
epithelial cells as it has been reported that thymic DC are also
involved in this process (Watanabe et al., 2005; Proietto et al.,
2008; Wirnsberger et al., 2009). Moreover, induction of Treg dif-
ferentiation by DC has also been reported in peripheral lymphoid
organs under certain carefully controlled experimental condi-
tions (reviewed by Romagnoli et al., 2008). It may therefore be
hypothesized that hematopoietic chimerism can lead to differ-
entiation and/or expansion of Treg speciﬁc for donor antigens
and thus to the development of dominant tolerance. However,
in experimental systems where the conditioning regimen used to
induce mixed hematopoietic chimerism involved the total dele-
tion of host T cells, transfer of syngeneic naïve CD4+ Tc e l l s
into the recipient leads to bone-marrow rejection and to the con-
comitant loss of donor-speciﬁc transplantation tolerance (Wren
et al., 1993). This result clearly demonstrated that hematopoi-
etic chimerism per se is insufﬁcient for induction of dominant
tolerance to alloantigens. Given the non-redundant role of Treg
in maintenance of self-tolerance,hematopoietic chimerism there-
fore appears unlikely to be sufﬁcient for permanent survival of
allografts.
Active tolerance mechanisms are not limited to those medi-
ated by Treg. “Immune deviation” from a harmful Th1 to a less
detrimental Th2 response has also been shown to play a role in
control of immune responses (Rocken, 1996; Walker and Abbas,
2002). Alloreactive Th2 cytokine producing T cells have been
observed after neonatal injection of lymphohematopoietic cells
(Streilein,1991)andimmunedeviationbyIL-4wasshowntoplay
a critical role in tolerance to alloantigens (Donckier et al., 1995).
Thehematopoietic(micro-)chimerisminducedinthisexperimen-
tal model, which is critically required for the allograft tolerance
(Lubaroff and Silvers,1973),therefore appears to induce an active
regulatory mechanism. However,this mechanism appears insufﬁ-
cientforinductionof fullimmunologicaltolerancetoalloantigens
(see below). Stem-cell transplantation under cover of cyclophos-
phamide can induce tolerance to MHC-matched skin allografts
in mice. It was shown that NKT cells, another immunoregula-
tory population, play a central role in this phenomenon (Iwai
etal.,2006).RegulatoryTcellpopulationsotherthanFoxp3+ cells
may therefore be induced by hematopoietic chimerism but their
activity appears insufﬁcient for prevention of chronic allograft
rejection.
DOES HEMATOPOIETIC CHIMERISM INDUCE GENUINE
TOLERANCE TO ALLOGRAFTS?
As discussed above, hematopoietic chimerism is thought to be
sufﬁcientforinductionof tolerancetoallografts.Themechanisms
involvedincludecentralandperipheralclonaldeletionandanergy.
After the initial reports on allograft tolerance in dizygotic cattle
twins that had shared blood circulation during embryonic life, it
became clear that most skin grafts were rejected in the long term
(Stone et al.,1965,1971). Second skin grafts from the same donor
survivedlesslongthantheﬁrstgrafts,butsubstantiallylongerthan
thirdpartyorgans,showingthatthetolerancemechanismhadnot
waned away.
Also neonatal injection of allogeneic splenocytes, leading to
hematopoietic microchimerism,is thought to induce tolerance to
subsequent skin grafts. However,this procedure appeared to work
only in a limited number of donor/host combinations. Impor-
tantly, most of the reported donor/host combinations concerned
MHC congenic strains (i.e., expressing distinct MHC haplotypes
on an identical genetic background) and chronic rejection was
not systematically studied (Streilein and Klein, 1977). Moreover,
even when acceptance of skin allografts was achieved, it did not
correlate with immunological unresponsiveness (Streilein, 1991;
Donckier et al., 1995).
In adult mice, lymphoablation was achieved using lethal
total body irradiation or depleting antibodies to, e.g., CD4 and
CD8. Myeloablation, required for induction of hematopoietic
chimerism, was induced by the irradiation or administration of
myeloablative drugs. Subsequent transplantation of allogenic or
xenogenic bone marrow led to persistent chimerism (reviewed in
WekerleandSykes,1999;CosimiandSachs,2004).Skingraftsfrom
thebone-marrowdonorscouldsurviveforprolongedperiods,but
success-rates were often well below 100% and chronic rejection
was not studied. In some host/donor combinations, hematopoi-
etic chimerism failed to prevent acute rejection of skin allografts
(Boyse et al., 1970), and T cell reactivity to skin-speciﬁc anti-
gens not expressed by hematopoietic cells was responsible for this
observation (Scheid et al., 1972; Boyse et al., 1973). Also the sur-
vivalofcardiacallograftswasfavoredbyhematopoieticchimerism
(Steinmuller and Lofgreen, 1974). However, histological analysis
of surviving hearts revealed frequent chronic rejection (Russell
et al., 2001). Also in the rat, myelo- and lymphoablation followed
by induction of hematopoietic chimerism was reported to pro-
longsurvivalof skin,heart,andrenalallografts(Slavinetal.,1978;
Colson et al., 1995b; Orloff et al., 1995; Blom et al., 1996). How-
ever, chronic rejection was seldom adequately studied. It appears
therefore that immunological tolerance to allografts is not sys-
tematically achieved by induction of hematopoietic chimerism in
lymphoablated recipients.
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Hematopoietic chimerism can also be induced with non-
lymphoablativeregimens.Surprisingly,undercertainofthesecon-
ditions, allografts appear to do better than when lymphoablative
conditioning is used (Table 1). Blocking the T cell co-stimulatory
molecule CD28 with an Ig-fusion protein of its CTLA4-ligand
(CTLA4-Ig), combined with inhibition of the CD40/CD40L (i.e.,
CD154) pathway involved in activation of antigen presenting and
B cells, substantially prolongs heart and skin allograft survival
(Larsen et al., 1996). However, histological signs of chronic rejec-
tionof cardiacallograftswasobservedinallthusconditionedmice
(Shirasugi et al., 2002). When co-stimulatory blockade was com-
bined with induction of hematopoietic chimerism, heart, skin,
and also intestine allografts survived substantially longer and no
chronic rejection was observed (Wekerle et al.,1998,2000;Adams
etal.,2001;Shirasugietal.,2002;Guoetal.,2003).Transplantation
tolerance in such settings was dominant and depended on Treg,at
least during early stages (Bigenzahn et al., 2005; Domenig et al.,
2005).
Combined, these data indicate that hematopoietic chimerism
per se appears insufﬁcient for induction of transplantation tol-
erance. However, when combined with conditioning regimens
that allow for development of dominant tolerance, prevention of
chronic rejection can be achieved.
INDUCTION OF HEMATOPOIETIC CHIMERISM: TOWARD THE
CLINIC
Given the very encouraging results obtained with mixed
hematopoietic chimerism in rodents, several groups have
attempted to induce hematopoietic chimerism and transplanta-
tion tolerance in large animal models (Wekerle and Sykes, 1999;
CosimiandSachs,2004;Horneretal.,2006).Experimentalproto-
colsarenecessarilymorecomplexthaninrodentssinceadultrecip-
ientswereusedandhighdosewholebodyirradiationisassociated
withatoohighlevelof morbidity.Acombinationof immunosup-
pressive drugs and antibodies,as well as lower levels of irradiation
or irradiation limited to lymphoid organs, was therefore used as
conditioning regimen (Table 2). In miniature swine, a precondi-
tioningof Tcelldepletion,lowdosetotalbodyirradiation,thymic
irradiation, and splenectomy, followed by bone-marrow and skin
transplantation,led to persistent hematopoietic chimerism in ﬁve
out of six animals. Four of these animals were transplanted with
donorskin.Half of theseanimalsappearedtoaccept,buttheother
halfrejectedtheskinallografts(Fuchimotoetal.,2000).Alsousing
amilderconditioningregimen,persistentchimerismwasobtained
in miniature swine and one out of two skin grafts appeared to be
permanently accepted (Fuchimoto et al., 2000). When the latter
protocol was used for kidney transplantation, four out of four
allografts survived more than 100days (Fuchimoto et al., 2000,
2001).Therefore,asobservedinrodents,persistenthematopoietic
chimerism led to an incomplete level of allograft tolerance that
appeared efﬁcient for protection of poorly immunogenic organs
suchaskidneybutfailstopreventrejectionofhighlyimmunogenic
skin allografts.
In Cynomolgus monkeys,a preconditioning regimen was used
that consisted of T cell depletion, low dose total body irradi-
ation, thymic irradiation, and splenectomy, followed by bone-
marrowandkidneytransplantation(Kawaietal.,1995,2002,2004;
Kimikawa et al.,1997b). Only transient hematopoietic chimerism
was observed, but nevertheless 8 out of 15 grafts did not show
signs of rejection (Table 2).An acute cellular rejection process led
to the loss of the other grafts (Kimikawa et al.,1997a; Kawai et al.,
1999). A similar preconditioning regimen was used for monkeys
that received a cardiac allograft. Three out of ﬁve animals devel-
oped transient chimerism, but all ﬁve hearts were eventually lost
by a rejection-process characterized by cellular inﬁltrates (Kawai
et al., 2002). The observation that kidney allografts were more
likelytobeacceptedthanheartallograftsconﬁrmedearlierdataon
transplantationinminiatureswinethat,interestingly,alsoshowed
that kidneys can play an important role in tolerance to heart allo-
grafts(Madsenetal.,1998;Mezrichetal.,2003a,b).Takentogether
these data highlight the difﬁculty to obtain an efﬁcient and per-
sistent engraftment of hematopoietic stem cells in large animal
models. When only transient, hematopoietic chimerism induces
tolerance mechanisms that are probably different from and less
efﬁcientthanthoseinducedinhostswithlong-termpersistenceof
hematopoietic donor cells.
INDUCTION OF HEMATOPOIETIC CHIMERISM: IN THE CLINIC
Based on the promising results in monkeys, induction of
hematopoietic chimerism for prevention of allograft rejection has
also been performed in humans (Table 3). Infusion of donor
bone-marrow showed some beneﬁcial effect in renal allograft
recipients (Monaco, 2003). Interestingly, in an early report in
which large numbers of patients were described, infusion of
donor bone marrow, leading to transient chimerism, inhibited
acute but not chronic rejection (Barber et al., 1991; McDaniel
et al., 1994). One of the ﬁrst reported cases of long-term allograft
survival achieved by induction of hematopoietic chimerism con-
cernedawomanwithend-stagerenaldiseasesecondarytomultiple
myeloma (Spitzer et al., 1999). The patient received an immuno-
suppressive but non-myeloablative conditioning regimen. HLA-
matched bone marrow and kidney from the patient’s sister were
transplanted and the immunosuppressive drug cyclosporine A
administered for 73days. Whereas the hematopoietic chimerism
disappeared after discontinuation of immunosuppression, the
kidney remained functional for at least another 7years (Fud-
aba et al., 2006). In total, six multiple myeloma patients receiv-
ing this treatment have been reported and all maintained renal
function after discontinuation of immunosuppression for 2–
7years (Spitzer et al., 1999; Buhler et al., 2002; Fudaba et al.,
2006). Stem-cell transfusion was also shown to have a beneﬁ-
cial effect in liver transplantation (Donckier et al.,2004). Another
example concerned a patient with end-stage renal disease who
receivedanHLA-matchedkidneygraft.Theconditioningregimen,
which included total lymphoid irradiation, immunosuppression,
and a graft of mobilized CD34+ stem cells, led to persistent
hematopoietic chimerism. At the time of publication, the renal
graft had remained functional for 34months (Scandling et al.,
2008).
Induction of hematopoietic chimerism followed by kidney
transplantation was also performed with HLA single haplotype
mismatched grafts (Kawai et al., 2008), a clinically important
setting. Five patients with end-stage renal disease received an
immunosuppressive but non-myeloablative preparative regimen
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Table 1 | Combined bone-marrow and organ transplantation in the mouse: non-myelo- and lymphoablative procedures.
BM/SC graft=>
host
Organ/tissue
graft
Conditioninga Hematopoietic
chimerismb
Allograft survival Reference
ANTIBODIES
No BM, C3H host BALB/c heart αCD154 and
CTLA4-Ig
7/7>day 70 (no
chronic rejection at
d63)
Larsen et al. (1996)
BALB/c skin 15/15>day 50 (no
chronic rejection at
day 50)
B10.A=>B6 B10.A skin αCD154 and
CTLA4-Ig
Persistent 8/8 at day 145 Wekerle et al. (2000)
Transient 1/5 at day 145
B10.A=>B6 B10.A skin αCD154 and
CTLA4-Ig,
sublethalTBI
Persistent 7/9 at day 160 Wekerle et al. (1998)
BALB/c=>B6 BALB/c skin αCD154 and
CTLA4-Ig, BUS
Persistent 7/7 at day 250 Adams et al. (2001)
BALB/c=>B6 BALB/c heart αCD154 and
CTLA4-Ig
Undetectable 8/9 at day 180,
chronic rejection at
day 300 in 8/8
hosts
Shirasugi et al. (2002)
αCD154 and
CTLA4-Ig, BUS
Persistent 5/5 at day 180, no
chronic rejection at
day 300
BALB/c=>B6 BALB/c
intestine
αCD154 and
CTLA4-Ig, BUS
Persistent 5/7 at day 92 Guo et al. (2003)
BALB/c=>B6 BALB/c skin αCD154 and
CTLA4-Ig, Rapa,
Treg
Persistent? 7/7 at day 170 Pilat et al. (2010)
BALB/c=>B6 BALB/c skin low doseTBI,
αCD154
Persistent 0/4 at day 60 Luo et al. (2007)
B6.C-H-2d skin 4/4>day 180
BALB/c=>B6 BALB/c skin αCD154
andαLFA-1
Persistent 4/7>day 270 Metzler et al. (2004)
αCD154 and Rapa 4/7>day 226
αCD154 and BUS
and various
22/24: chronic
rejection
BALB/c heart 4/24: mild chronic
rejection
BALB/c skin αLFA-1 and Rapa 0/6 day 117
BALB/c=>B6 BALB/c
pancreatic
islets
Rapa, low dose
TBI
Persistent 6/6>day 100 Luo et al. (2005)
B10.BR=>CBA B10.BR skin αCD4
andαCD8(nd)
Persistent 8/8 at day 240 Qin et al. (1990)
B10 DST=>C3H C3H heart αCD4(nd) N/D 7/7 at day 100 Pearson et al. (1992)
DRUGS
BALB/c=>B6 BALB/c skin SC, CP , αThy1 Persistent 10/15 at day 159 Mayumi and Good (1989)
BALB/c=>C3H BALB/c skin 7/8 at day 165
B6=>C3H B6 skin 4/9 at day 185
C3H=>B6 C3H skin 0/19 (chronic
rejection)
B10.BR or
BALB/c=>B10
B10.BR or
BALB/c skin
SublethalTBI, CP Persistent 9/10 at day 60 Colson et al. (1995a)
(Continued)
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Table 1 | Continued
BM/SC graft=>
host
Organ/tissue
graft
Conditioninga Hematopoietic
chimerismb
Allograft survival Reference
BALB/c=>B10 BALB/c heart 6/6>day 420
B10.A(5R)=>B10 B10.A(5R) skin SC, CP Transient 4/10 at day 200 Tomita et al. (1990b)
C3H=>AKR C3H skin SC, CP Transient 5/8 at day 100=> Tomita et al. (1990a)
B10.BR=>AKR B10.BR skin 5/6 at day 100
AKR=>C3H AKR skin 5/8 at day 100
B10.BR=>C3H B10.BR skin 4/8 at day 100
B10.D2=>BALB/c B10.D2 skin 5/6 at day 100
B10=>AKR B10 skin 0/6 at day 12
B6=>C3H B6 skin 0/6 at day 13=>
B6=>AKR B6 skin 0/6 at day 12
AKR SC=>C3H AKR skin CP Persistent 9/10, day 120 Eto et al. (1990)
AKR SC=>C3H B10.BR skin 0/5 at day 13
B10.BR SC=>C3H B10.BR skin 10/10 at day 120
B10.BR SC=>C3H AKR skin 0/5 at day 14
DBA/2=>BALB/c DBA/2 skin 8/10 at day 80
DBA/2=>BALB B10.D2 skin 0/5 at day 13
DBA/2
SC=>BALB/c wt
DBA/2 skin CP Persistent 6/6 at day 100 Iwai et al. (2006)
DBA/2 SC=>Vα14
NKT KO
0/6 at day 50
B10.A=>B6 B10.A skin αCD4(d) and
αCD8(d), CP ,TI,
TBI
Persistent 6/6 at day 100 Mapara et al. (2001)
aα, antibody to; BUS, busulfan; CP , cyclophosphamide; nd, non-depleting; SC, CD34+ stem cells;TBI, total body irradiation;TI, thymic irradiation;Treg, CD4+CD25+
regulatoryT cells.
bN/D, not detected.
and a combined bone-marrow/renal allograft. All developed a
transient multi-lineage chimerism. Whereas one patient lost the
allograft by acute humoral rejection 10days post transplanta-
tion, four out of the ﬁve patients, treated with a combination
of immunosuppressive drugs for up to 14months, maintained
renal function for up to 1400days thereafter. Renal biopsies
showed normal tissue for three of these patients, with some
minor signs of chronic rejection for the fourth. In vitro studies
suggested speciﬁc absence of T cell-responses to directly pre-
sented alloantigens. However, two out of the four patients later
developed alloantibodies, one showing complement depositions
in the graft (Porcheray et al., 2009). It needs to be empha-
sized that T cell reactivity to indirectly presented donor antigens
is required for alloantibody-production by host B-lymphocytes.
The apparent absence of T cell response to directly presented
alloantigens and the production of alloantibodies are therefore
not in contradiction. Combined, these studies suggested that
long-term acceptance of (though not genuine immunological
tolerance to) kidney allografts can be obtained by a therapy
including induction of transient hematopoietic chimerism and
therefore represented a major step forward in transplantation
medicine.
Less promising results were obtained in a study in which HLA-
mismatchedpancreaticisletsweretransplantedintotypeIdiabetes
patients (Mineo et al., 2008). The conditioning regimen used
was very mild but nevertheless led to transient hematopoietic
chimerism. However, all four patients that initially adhered to
immunosuppressive therapy lost graft-function rapidly after drug
weaning.
A ROLE FOR REGULATORY T CELLS IN HEMATOPOIETIC
CHIMERISM-ASSOCIATED TOLERANCE?
At this point, one might wonder if more work is warranted to
obtaintoleranceto(andthereforepermanentacceptanceof)organ
allografts. When considering the very promising results obtained
withkidneyallograftsinhumans,onehastokeepinmindthatthis
organ might represent a special case. The human islet study failed,
andthemonkeyandswinestudiesgavesubstantiallylesssatisfying
results with skin and heart allografts than with renal transplants.
Moreover, in miniature swine it was shown that kidney allografts
induced tolerance to heart allografts (Madsen et al., 1998). The
thymus and Treg may play a role in this phenomenon (Yamada
et al.,1999; Mezrich et al., 2003a).
To induce genuine immunological tolerance to donor tissues,
hematopoieticchimerismneedstopersistinthelongtermtocon-
tinuously induce tolerance of newly developing lymphocytes in
primary lymphoid organs. Indeed, if hematopoietic chimerism is
only transient, mature allospeciﬁc lymphocytes will develop and,
in the absence of dominant tolerance mechanisms, will eventu-
ally destroy the graft. Long-term hematopoietic chimerism has
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Table 2 | Combined bone-marrow and organ transplantation in large animals and non-human primates.
Species Organ Conditioninga Immuno-
suppression
Hematopoietic
chimerismc
Allograft
survivald
Reference
“Cattle” Skin Co-twins None Persistent 30% at 2years Stone et al. (1971)
Body
skin
Co-twins None Persistent 0/10 at day 68 Emery and McCul-
lagh (1980)
Auricular
skin
5/12>day 60
Dog Heart TLI, donor BM ±ATG, ±MTX,
±CsA
N/A 0/29 at day 329 Strober et al. (1984)
Kidney ALS, donor BM None N/A >14b, >17b, >38b, >78b
d,≤4/24
Caridis et al. (1973)
Kidney ALS, donor BM None N/A 0/13 at day 300 Hartner et al. (1986)
Miniature
swine
Kidney LethalTBI±CP None Persistent >200, >200, >200, >200,
75
Guzzetta et al. (1991)
Skin αCD3-DT;TBI;TI; donor
BM
30days CsA Persistent 45, 50, >50, >235days Huang et al. (2000)
Skin αCD3-DT;TI; donor
PBSC
30days CsA Persistent >300, 45days Fuchimoto et al.
(2000)
Kidney >120, >180, >100days,
“long term”
Fuchimoto et al.
(2000, 2001)
Rhesus
monkey
Kidney ATG, donor BM None N/A 20% at day 240 Thomas et al. (1983,
1987)
Cynomolgus
monkey
Kidney ATG;TBI;TI;
splenectomy; donor BM
4weeks CsA Transient >3478, >2569, >834e,
>771e, >405e, 260,
>198e, >196e, >137e, 72,
44, 40, 37 , 40, 37days
Kawai et al. (1995),
Kimikawa et al.
(1997b), Kawai et al.
(2002, 2004)
N/D 14, 175days
Heart Transient 509, 428, 138days
N/D 56, 43days
Kidney ATG;TBI;TI; donor BM 4weeks CsA Transient 117, 95, 43
Kidney ATG;TBI;TI; donor BM;
aCD154
4weeks CsA Transient >1710, >1167 , 755, 206,
837 , 401, 373, 58
Kawai et al. (2004)
aα, antibody to; αCD3-DT, anti-CD3 antibody coupled to diphtheria toxin; ALS, anti-lymphocyte serum; ATG, antithymocyte globulin; BM, bone marrow; CP , cyclophos-
phamide; PBSC, peripheral blood stem cells;TBI, total body irradiation;TI, thymic irradiation;TLI, total lymphoid irradiation.
bRenal allografts that were not rejected but were lost for other reasons.
cN/A, not analyzed; N/D, not detected.
dAnimals that rejected their allografts are indicated in bold.
eRenal allografts that were not rejected but were lost for other reasons.
been achieved with very aggressive conditioning regimens induc-
ing total host T cell depletion. However, the level of toxicity and
the severe immunosuppression associated with this type of treat-
ment do not allow their use in the clinic.Alternative conditioning
regimens have been envisaged to avoid rejection of donor bone
marrowwhileallowingforsurvivalof partof thehostTcells.They
included the injection of non-depleting antibodies to block T cell
co-stimulatory pathways and the injection of antibodies speciﬁc
forsomeTcellmarkersupregulateduponactivation.Asdescribed
throughoutthisreview,thesemethodsgaveverypromisingresults
in rodents. However, induction of a permanent chimerism was
far more difﬁcult to achieve in large animals. This observation
might be largely responsible for the less satisfying results obtained
with heart and skin allograft in miniature swine and primates.
Moreover,antibody-basedtherapiescanalsogenerateunpredicted
side effects that complicate translation into the clinic. For exam-
ple, the use of anti-CD154 antibody in a non-human primate
renalallograftmodelledtoseverethromboemboliccomplications
(Kawai et al., 2000; Koyama et al., 2004) due to CD154 expres-
siononactivatedplateletsandtoCD40expressiononthevascular
endothelium (Henn et al., 1998; Slupsky et al., 1998). The use
of anti-CD154 has also been associated with impaired humoral
immunity against inﬂuenza in a heart allograft model (Crowe
et al.,2003).Antibodies targeting other T cell surface markers also
presentlimitationsastargetedmoleculescanbeexpressedbyother
populations, e.g., CD25 on Treg. While inhibiting the allogeneic
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Table 3 | Combined bone-marrow and organ transplantation in humans.
Organ Conditioninga Immuno-
suppressiona
Hematopoietic
chimerismc
Allograft
survivalb
Reference
Kidney
(HLA-matched)
ALG; CP Maintenance CsA;
azathioprine; prednisone
N/A 13/54 rejected Barber et al. (1991)
ALG; CP; donor BM 3/57 rejected
Kidney Donor BM 2weeks
ALG+maintenance
Persistent
microchimerism
21/23 at 1year (but
“chronic rejection”)
McDaniel et al. (1994)
Transient/ND 1/7 at 1year
Kidney
(haplocompatible)
TBI, ARA-C, CP , ATG
(splenectomy)
10months CsA, Pred Persistent >15months Sorof et al. (1995)
Kidney (related
donors)
Not speciﬁed, prior BM
transplantation to treat
hematological disorders
None Persistent >15, >30, >3months Butcher et al. (1999)
Kidney
(HLA-matched)
CP; ATG;TI; donor BM 2months CsA Transient/persistent >7 .3, >5.3, >4.3, >3.5,
>2.8, >2years
Spitzer et al. (1999),
Buhler et al. (2002),
Fudaba et al. (2006)
Kidney
(HLA-matched)
ATG;TLI; donor PBSC 6months CsA Persistent >34months Scandling et al. (2008)
Kidney
(HLA-mismatched)
CP; αCD2;TI; donor BM ≤14months CsA/Rapa Transient >1932, >1666, 10days,
>1050, >707days;
donor-speciﬁc antibodies
Kawai et al. (2008),
Porcheray et al. (2009)
Pancreatic islet
(HLA-mismatched)
High dose HSC 1year “Edmonton”
(FK506, Rapa)
Transient 451, 480, 178, 471, 158,
510days
Mineo et al. (2008)
Liver ATG; CP; donor HSC 28–90days FK506, Rapa Transient/ND >240, >290 Donckier et al. (2004)
aα, antibody to; ALG, anti-lymphocyte globulin; ARA-C, arabinofuranosyl cytidine; ATG, antithymocyte globulin; BM, bone marrow; CsA, cyclosporin A; CP , cyclophos-
phamide; HSC, CD34+ hematopoietic stem cells; PBSC, peripheral blood stem cells; Pred, prednisone; Rapa, Rapamycin; TBI, total body irradiation; TI, thymic
irradiation;TLI, total lymphoid irradiation.
bPatients that rejected their allografts are indicated in bold.
cN/A, not analyzed; N/D, not detected.
response, such approaches could therefore prevent the establish-
mentof regulatorymechanismsimportantforgraftsurvival.They
also non-speciﬁcally inhibit T cell-dependent immunity, includ-
ing protective responses against pathogens. Finally, most of the
protocols used in large animals or currently tested in the clinic
require strong initial immunosuppressive treatments that induce
major qualitative and quantitative modiﬁcations of the immune
system that last for years. In conclusion, while highly promising,
these strategies still need to be optimized before going into the
clinic.
To overcome the issues listed above, several laboratories
embarked on studies to evaluate the potential of Treg to pro-
mote allograft protection (reviewed by Li and Turka, 2010).
The capacity of naturally occurring Treg to control allogeneic
responses was already highlighted by Sakaguchi et al. (1995)
landmark paper. Using in vivo activated polyclonal Treg with
irrelevant speciﬁcity, Karim et al. (2005) ﬁrst induced tol-
erance to allogeneic skin graft in lymphopenic Rag-deﬁcient
hosts reconstituted with naïve CD45RBhigh CD4+T cells (Karim
et al., 2005). Similar results were obtained in another lym-
phopenic system with in vitro expanded donor-speciﬁc Treg
(Golshayan et al., 2007). Interestingly, this approach also sig-
niﬁcantly prolonged skin allograft survival in unmanipulated
wild-type hosts. In a transplantation-model across minor his-
tocompatibility antigens, another group protected male skin
graft from rejection by syngeneic female hosts using Foxp3-
transduced male antigen-speciﬁc TCR transgenic CD4+ Tc e l l s
(Chai et al., 2005). In another study, a genetically manipulated
Treg population with direct and indirect alloantigen-speciﬁcity
substantiallyprolongedskinallograftsurvivalanddelayedchronic
rejection of heart allografts when co-injected with anti-CD8
antibody (Tsang et al., 2008). More recently, prevention of
transplant arteriosclerosis and long-term survival of skin allo-
graft were achieved with in vitro expanded naturally occurring
CD127lowCD25+CD4+ human Treg in a chimeric humanized
mouse system (Issa and Wood, 2010; Nadig et al., 2010). Com-
bined, these reports demonstrated the capacity of Treg to delay
rejection processes.
Based on the large body of literature on transplantation toler-
ance through hematopoietic chimerism and on the immunosup-
pressive potential of Treg,several laboratories decided to combine
Treg infusion with bone-marrow transplantation (Figure1). This
method is expected to allow the establishment of complementary
tolerance mechanisms, thus mimicking the complex network of
checkpoints and regulatory systems naturally involved in mainte-
nance of self-tolerance (Figure 2). Moreover, in addition to their
generalmodulatoryeffectsonthereactivityoftheimmunesystem,
TregexpressingthetranscriptionfactorFoxp3havethecapacityto
establish an immune-privileged niche for allogeneic hematopoi-
etic stem cells after transplantation into non-irradiated recipients
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FIGURE 1 |A regulatoryT cell/hematopoietic chimerism-based
protocol for induction of transplantation tolerance. (1)The allograft
(e.g., heart) will be transplanted with concomitant infusion of donor
BM or HSC into conditioned hosts. Rejection of the grafts will temporarily be
prevented using an immunosuppressive regimen. (2) Donor (a) and host (b)
BM will be cultured in vitro under conditions allowing for differentiation of DC.
Host DC will be pulsed with donor antigen to assure indirect presentation of
these antigens.Thus generated DC will then be co-cultured with host-derived
Treg (c), allowing for expansion ofTreg speciﬁc for directly and indirectly
presented donor antigens. (3)Thus generated donor-antigen-speciﬁcTreg will
then be infused into the host. Immunosuppression may temporarily be
continued using drugs that do not affectTreg (e.g., Rapamycin). Using this
protocol, full tolerance to donor-tissue will be achieved and chronic rejection
effectively prevented.
(Fujisaki et al., 2011). The co-injection of Treg with allogeneic
bone-marrowshouldthereforepromoteitsengraftment.Adminis-
trationofdonor-speciﬁcTregpreventedrejectionofbone-marrow
allografts in preconditioned mice (Joffre et al., 2004; Joffre and
van Meerwijk, 2006). Promising results were later obtained using
polyclonal donor Treg (Hanash and Levy,2005). However,similar
protocols failed to substantially prolong survival of skin and heart
allografts (Joffre et al., 2008; Tsang et al., 2008; Pilat et al., 2010).
In contrast, when combined with bone-marrow transplantation,
administration of a single dose of Treg fully prevented rejection
of skin and heart (Joffre et al., 2008). Whereas Treg speciﬁc for
directly presented donor-antigens allowed for survival of bone-
marrow allografts, they failed to prevent chronic rejection of skin
andheart.Incontrast,Tregspeciﬁcforindirectlypresenteddonor-
antigens fully prevented chronic heart and skin allograft rejection
(Joffre et al.,2008). These results ﬁrmly demonstrated the clinical
potentialofTreginfusionininductionofbone-marrowchimerism
and in the subsequent prevention of acute and chronic allograft
rejection.
TREG AND HEMATOPOIETIC CHIMERISM-BASED
STRATEGIES: SOME LIMITATIONS TO OVERCOME
Thedatadescribedaboveconstituteaproof of principlethatcom-
bining Treg and bone-marrow infusion can lead to subsequent
tolerance to allogeneic tissues, even in very stringent donor/host
combinations and for highly immunogenic tissues such as the
skin. However, 5Gy total body irradiation was required in that
protocol (Joffre et al., 2008). This dose appears not suitable for
clinical use as it is associated with severe temporary leukopenia.
Interestingly,thegroupofWekerlerecentlyinducedhematopoietic
chimerism in mice using a comparable approach, but without or
with very limited cytoreductive conditioning (Pilat et al., 2010,
2011). Treatment with costimulation-blocking agents, a short
course of rapamycin, and injection of polyclonal Treg allowed for
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FIGURE 2 |Tolerance mechanisms induced by the proposed
regulatoryT cell/hematopoietic chimerism-based protocol for
induction of transplantation tolerance. (1) Hematopoietic cells
(e.g., DC) derived from the grafted BM will colonize the recipient’s
thymus and induce deletion and anergy (i.e., “recessive tolerance”) of
developing donor-speciﬁc hostT lymphocytes. DC may also promote
limited differentiation of donor-speciﬁcTreg that will contribute to
transplantation tolerance. (2) Donor DC will also induce recessive
tolerance of mature peripheral donor-speciﬁcT lymphocytes.These
cells may, to a limited extent, directly induce donor-speciﬁcTreg.
However, the dominant tolerance (i.e.,Treg) induce by hematopoietic
chimerism in (1) and (2) appears insufﬁcient to durably prevent most notably
chronic allograft rejection. (3) Infusion of donor-speciﬁcTreg will aid in
engraftment of grafted donor BM/HSC (a) and inhibit the reactivity of mature
peripheral donor-speciﬁcT lymphocytes (b), thus favoring graft-acceptance.
They will also allow the differentiation of donor-speciﬁc conventionalT
lymphocytes intoTreg (c), thus assuring persistence of tolerance and
preventing chronic allograft rejection.
induction of hematopoietic chimerism. Skin grafts transplanted
on these mice survived for more than 160days, without signs of
rejection or appearance of donor-speciﬁc antibodies (Pilat et al.,
2010). More recently, this group raised similar conclusions using
polyclonal host CD4+ lymphocytes previously transduced with
a retroviral vector containing Foxp3 and a drug-free condition-
ing regimen where 1Gy total body irradiation replaced the short
course of rapamycin (Pilat et al., 2011). These protocols repre-
sent a major step forward to the clinic. However, they still rely on
anti-CD154 treatment and this antibody is presently not usable
in patients (see above). Different non-mutually exclusive strate-
gies can be envisaged to avoid co-stimulatory-blockade. The use
of hematopoietic or mesenchymal stem cells instead of bone-
marrow cells could be an option, as this will signiﬁcantly reduce
the immunogenicity of the graft. Another strategy would be to
improve the efﬁciency of the immunosuppression by injecting
donor-speciﬁc Treg. Alloantigen-speciﬁc T cells survived longer
and in several transplantation models gave substantially better
resultsthanpolyclonalTregswithirrelevantspeciﬁcity(Joffreetal.,
2004, 2008; Nishimura et al., 2004; Golshayan et al., 2007).
Another aspect that still needs to be tested before translat-
ing Treg-based strategies into the clinic is represented by the
antigen-speciﬁcity of the treatments. Indeed, if Treg activation is
antigenspeciﬁc,thesecellsexerttheirsuppressoreffectorfunction
inanon-antigen-speciﬁc-mannerinvitro(ThorntonandShevach,
2000). If true in vivo, infused Treg may therefore inhibit protec-
tive immunity. However, it has been shown that hematopoietic
chimerism/Treg-based therapy against allograft rejection is (at
least) donor speciﬁc. A related issue is that tolerance to donor-
antigenmaybebrokenby(e.g.,viral)infection(Welshetal.,2000;
Williams et al., 2001; Forman et al., 2002). It therefore also needs
to be veriﬁed to what extent Treg-based therapies are resistant to
infection. Experimental work will need to be performed to clarify
these important issues.
Finally,infused Treg do not necessarily survive indeﬁnitely and
tolerance may therefore wane away with time. In other trans-
plantation models, however, it was shown that a tolerant T cell
population can render naïve T cells tolerant and even tolerogenic
(Waldmann, 2010). Very recently it was shown that this so-called
“infectious tolerance” depends on Treg that induce novel Treg
required for persistence of tolerance to allografts (Kendal et al.,
2011). Even if it remains to be shown that also infused Treg can
causeinfectioustolerance,itappearsthereforethatTregcaninduce
life-long tolerance to allografts.
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CONCLUSION
The data discussed here indicate that induction of persistent
hematopoietic chimerism combined with infusion of Treg with
appropriate speciﬁcity efﬁciently leads to life-long tolerance to
allograftsinexperimentalanimalmodels(Figure1).Thus,andnot
very surprisingly so,the mechanisms involved in the maintenance
of tolerance to self antigens also appear required for tolerance to
donor antigens (Figure 2). More work will need to be performed
to establish conditioning regimens compatible with clinical con-
straints and to assess immunocompetence of grafted animals. The
validityoftheseconclusionsfornon-humanprimatesandhumans
remains to be studied.Very substantial progress has been made in
recentyearsintheinductionofauthenticimmunologicaltolerance
to allogeneic organ grafts, and transplant recipients may soon be
abletolivealifefreeof thefearof losingthegraftandof thesevere
side effects of immunosuppressive drugs.
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